Research
JPMorgan Downgrades Replimune Group to Underweight From Neutral, $10 Price Target
Replimune Group (REPL) has an average rating of Hold and mean price target of $4, according to analysts polled by FactSet.
$REPL
$REPL
29 stories mentioning REPLUpdated 34d ago
Every FINWIRES story that references REPL, newest first.
What are analysts saying about REPL?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on REPL?
Research
BMO Capital Downgrades Replimune to Underperform From Market Perform, Adjusts PT to $1 From $11
Replimune Group (REPL) has an average rating of Hold and mean price target of $4, according to analysts polled by FactSet.
$REPL
Research
Cantor Fitzgerald Downgrades Replimune Group to Neutral From Overweight
Replimune Group (REPL) has an average rating of Hold and mean price target of $4, according to analysts polled by FactSet.
$REPL
Research
Leerink Partners Downgrades Replimune Group to Market Perform From Outperform, Adjusts Price Target
Replimune Group (REPL) has an average rating of Hold and mean price target of $4, according to analysts polled by FactSet.
$REPL
Research
HC Wainwright Downgrades Replimune to Sell From Buy
Replimune Group (REPL) has an average rating of Hold and mean price target of $4, according to analysts polled by FactSet.
$REPL
Research
Wedbush Downgrades Replimune Group to Neutral From Outperform, Cuts Price Target to $2 From $19
Replimune Group (REPL) has an average rating of hold and mean price target of $7.40, according to analysts polled by FactSet.
$REPL
Sectors
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.4%.The iShares Biotechnology ETF (IBB) shed 1.7%.In corporate news, AbbVie (ABBV) is expected to report Q1 earnings within its guidance range, but that may not be enough to improve sentiment toward the drugmaker, RBC Capital Markets said in a client note. The brokerage expects AbbVie to report per-share earnings of $2.59 for the first quarter, while the current consensus on FactSet is for non-GAAP EPS of $2.83. AbbVie shares were down 2.1%.Replimune (REPL) shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories (ABT) has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.7%.Organon (OGN) is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Times reported. Organon shares surged 27%.
$ABBV$ABT$OGN$REPL
Sectors
Sector Update: Health Care Stocks Lower Friday Afternoon
Health care stocks declined Friday afternoon, with the NYSE Health Care Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1.2%.The iShares Biotechnology ETF (IBB) dropped 1.8%.In corporate news, Replimune (REPL) shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories (ABT) has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.9%.Organon (OGN) is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Times reported. Organon shares surged 23%.
$ABT$OGN$REPL
Sectors
Sector Update: Health Care
Health care stocks declined Friday afternoon, with the NYSE Health Care Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1.2%.The iShares Biotechnology ETF (IBB) dropped 1.8%.In corporate news, Replimune's (REPL) shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.
$REPL
Showing 21-29 of 29
